Susmed

Susmed FCF Yield

The Free Cash Flow Yield of Susmed (4263.T) as of Oct 29, 2026 is -3.34 %. In the previous year, Free Cash Flow Yield was -2.66 % — a change of 25.57% (lower).

FCF Yield

-3.34 %

YoY

25.57%

Last updated:

Free Cash Flow Yield of Susmed is 2026 -3.34 % . Free Cash Flow Yield of Susmed was 2025 -2.66 % . It decreases by 25.57% lower compared to the previous year.

The Susmed FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2020
-0.57 JPY
Jan 1, 2021
-1.46 JPY
Jan 1, 2022
-1.08 JPY
Jan 1, 2023
0.50 JPY
Jan 1, 2024
-1.46 JPY
Jan 1, 2025
-2.66 JPY
Jan 1, 2026
-3.34 JPY
The Susmed FCF Yield history
YEARFCF YieldYoY
-3.34 %+25.57%
-2.66 %+81.97%
-1.46 %-391.30%
0.50 %-146.32%
-1.08 %-25.72%
-1.46 %+157.00%
-0.57 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Susmed Stock analysis

What does Susmed do? SUSMED, Inc. generates revenue through its DTx Product segment, which develops application software for treating insomnia, breast cancer, and chronic kidney diseases. The DTx Platform segment provides clinical trial systems, machine learning analysis systems, and DTx development support services. The company's primary customers are healthcare providers and pharmaceutical companies seeking digital therapeutics solutions. SUSMED targets the healthcare technology market with its specialized software and support services for disease treatment and clinical research. The DTx Product segment focuses on creating therapeutic applications for specific medical conditions, while the DTx Platform segment offers infrastructure for clinical trials and machine learning analysis. SUSMED's business model relies on selling both its proprietary software products and platform services to healthcare institutions and pharmaceutical firms. The company's revenue streams include software licensing, system subscriptions, and development support fees. SUSMED's products are designed to address chronic conditions like insomnia and breast cancer, with additional focus on chronic kidney diseases. The DTx Platform serves as a comprehensive solution for clinical trial management and machine learning-driven analysis, supporting pharmaceutical companies in their drug development processes. The company's services are tailored to meet the needs of healthcare technology providers and pharmaceutical developers. Susmed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Susmed stock

Free Cash Flow Yield of Susmed is -3.34 % in 2026.

Free Cash Flow Yield of Susmed changed from -2.66 % to -3.34 %, representing a 25.57% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Susmed since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Susmed with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Susmed

All Key Metrics — Susmed